In clinical trials, ZEPOSIA demonstrated efficacy on a key clinical marker of disease activity – annualized relapse rate (ARR) – as compared to AVONEX ® (interferon beta-1a)1 ,2,3
ZEPOSIA is a sphingosine-1-phosphate (S1P) receptor modulator that requires no label-based first dose observation 1
ZEPOSIA adds to Bristol Myers Squibb’s legacy immunology franchise and marks the first FDA-approved New Drug Application since the Celgene acquisition
PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S.
Media Inquiries: Media@bms.com 609-252-3345 Susan Francis Susan.firstname.lastname@example.org 609-529-0676 Investors: Tim Power Timothy.email@example.com 609-252-7509
Ticker: BMY Exchange: NYSE
#FDA approves new $BMY oral treatment option for #MultipleSclerosis #MS